Effects of Tai Chi Chuan With Different Doses on Cognitive Function in Elderly Patients With Mild Cognitive Impairment
NCT06372535, Not applicable, Unknown, Lidian Chen
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Tai Chi Chuan With Different Doses on Cognitive Function in Elderly Patients With Mild Cognitive Impairment | ClinicalTrials.gov |
| NCT number | NCT06372535 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 540 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Lidian Chen | ClinicalTrials.gov |
| Conditions | Mild Cognitive Impairment | ClinicalTrials.gov |
| Interventions | Tai Chi Chuan （dose 1）, Tai Chi Chuan （dose 2）, Tai Chi Chuan （dose 3）, Tai Chi Chuan （dose 4）, Tai Chi Chuan （dose 5）, Tai Chi Chuan （dose 6）, Tai Chi Chuan （dose 7）, Tai Chi Chuan （dose 8）, Tai Chi Chuan （dose 9） | ClinicalTrials.gov |
| First posted | 2024-04-18 | ClinicalTrials.gov |
| Last updated | 2024-04-18 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Montreal Cognitive Assessment | 8 weeks, 16 weeks, 24 weeks | Global cognition | ClinicalTrials.gov |
| Secondary | Montreal Cognitive Assessment | 52 weeks | Global cognition | ClinicalTrials.gov |
| Secondary | Wechsler Memory Scale | 8 weeks[the duration of intervention arm greater than or equal 8 weeks], 16 weeks [the duration of intervention arm greater than or equal 16 weeks], 24 weeks [the duration of intervention arm is 24 weeks] and 52 weeks | Memory function | ClinicalTrials.gov |
| Secondary | Digital Symbol test | 8 weeks[the duration of intervention arm greater than or equal 8 weeks], 16 weeks [the duration of intervention arm greater than or equal 16 weeks], 24 weeks [the duration of intervention arm is 24 weeks] and 52 weeks | Attention | ClinicalTrials.gov |
| Secondary | Trial Making Test part B | 8 weeks[the duration of intervention arm greater than or equal 8 weeks], 16 weeks [the duration of intervention arm greater than or equal 16 weeks], 24 weeks [the duration of intervention arm is 24 weeks] and 52 weeks | Executive function | ClinicalTrials.gov |
| Secondary | Stroop color word test | 8 weeks[the duration of intervention arm greater than or equal 8 weeks], 16 weeks [the duration of intervention arm greater than or equal 16 weeks], 24 weeks [the duration of intervention arm is 24 weeks] and 52 weeks | Processing speed | ClinicalTrials.gov |
| Secondary | Boston naming test | 8 weeks[the duration of intervention arm greater than or equal 8 weeks], 16 weeks [the duration of intervention arm greater than or equal 16 weeks], 24 weeks [the duration of intervention arm is 24 weeks] and 52 weeks | Verbal fluency | ClinicalTrials.gov |
| Secondary | Rey-Osterrieth complex graphics test | 8 weeks[the duration of intervention arm greater than or equal 8 weeks], 16 weeks [the duration of intervention arm greater than or equal 16 weeks], 24 weeks [the duration of intervention arm is 24 weeks] and 52 weeks | Rey-Osterrieth complex graphics test | ClinicalTrials.gov |
| Secondary | Rey Auditory Verbal Learning Test | 8 weeks[the duration of intervention arm greater than or equal 8 weeks], 16 weeks [the duration of intervention arm greater than or equal 16 weeks], 24 weeks [the duration of intervention arm is 24 weeks] and 52 weeks | Episodic memory | ClinicalTrials.gov |
| Other | Blood glucose metabolism index | 8 weeks or 16 weeks or 24 weeks [post-intervention] and 52weeks | fasting blood glucose | ClinicalTrials.gov |
| Other | Blood lipid metabolism index | 8 weeks or 16 weeks or 24 weeks [post-intervention] and 52weeks | total cholesterol (TC), total triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein (HDL) | ClinicalTrials.gov |
| Other | Functional Magnetic Resonance Imaging | 8 weeks or 16 weeks or 24 weeks [post-intervention] | Functional Magnetic Resonance Imaging | ClinicalTrials.gov |
| Other | Electroencephalogram | 8 weeks or 16 weeks or 24 weeks [post-intervention] | 1. Resting-State Electroencephalogram (EEG) Power Spectrum Changes. The power spectrum density of the brain in a relaxed state is measured using a resting-state electroencephalogram (EEG) for the delta (1-4 Hz), theta (4-8 Hz), alpha (8-13 Hz), beta (13-30 Hz), and gamma (30-100 Hz) bands. Changes in the power of these frequency bands before and after the intervention are assessed to reflect changes in the level of brain activity. 2. Task-Related Brain Electrophysiological Activity While performing specific cognitive tasks, brain activity is recorded using an Electroencephalogram (EEG), and task-related EEG event-related potentials are analyzed. | ClinicalTrials.gov |
| Other | Heart rate variability | 8 weeks or 16 weeks or 24 weeks [post-intervention] | cardiac autonomic modulations | ClinicalTrials.gov |
| Other | Gut microflora | 8 weeks or 16 weeks or 24 weeks [post-intervention] and 52weeks | 16S rRNA amplification sequencing will be used to detect intestinal microbiota. Stool sample from each sub center will be stored within 1 h of collection at - 80 °C freezer. Subsequently, the fecal samples will be stored in dry ice and transported in batches to the laboratory within 8 hours, followed by storage in - 80 °C freezer. | ClinicalTrials.gov |
| Other | Sleep Quality | 8 weeks or 16 weeks or 24 weeks [post-intervention] and 52weeks | The Pittsburgh Sleep Quality Index will be used to evaluate sleep quality, with a total score of 0-21. The higher the score, the poorer the sleep quality. | ClinicalTrials.gov |
| Other | General health | 8 weeks or 16 weeks or 24 weeks [post-intervention] and 52weeks | 12-Item Short Form Health Survey will be used to evaluate general health. the higher the total score, the better the individual's health status. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Picture Naming Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)